Sarepta to charge $300K for Duchenne drug that might not even work: ‘We tried to be reasonable’
Dr. Edward Kaye (LinkedIn)
Don't miss stories. Follow Raw Story!
The newly approved Sarepta Therapeutics drug for Duchenne muscular dystrophy will cost about $300,000 a year for the average patient in the United States, which is less than what some Wall Street analysts had expected. Sarepta CEO Dr. Edward Kaye said the pricing was “in the middle of the range” for rare disease drugs. “And given…
Next on Raw Story >
By commenting, you agree to our terms of service and to abide by our commenting policy.
Read Comments - Join the Discussion
SIGN UP FOR OUR NEWSLETTER